AtriCure (ATRC) Research & Development (2010 - 2026)

AtriCure (ATRC) has reported Research & Development for 17 consecutive years, with $26.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 9.84% year-over-year to $26.4 million in Q2 2026; TTM through Jun 2026 was $98.0 million, a 9.0% decrease from a year earlier, with the FY2025 full-year figure at $99.2 million, up 3.15% from the prior year.
• Research & Development was $26.4 million for Q2 2026 at AtriCure, up from $24.2 million in the prior quarter.
• Over five years, Research & Development peaked at $35.0 million in Q4 2024 and troughed at $13.6 million in Q1 2022.
• A 5-year average of $21.0 million and a median of $20.6 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 68.09% in 2024 and declined 29.9% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $13.7 million in 2022, then soared by 51.27% to $20.8 million in 2023, then soared by 68.09% to $35.0 million in 2024, then dropped by 29.9% to $24.5 million in 2025, then grew by 7.74% to $26.4 million in 2026.
• The last three Research & Development figures came in at $26.4 million (Q2 2026), $24.2 million (Q1 2026), and $24.5 million (Q4 2025), per Business Quant data.